LEADER 04084nam 2200973z- 450 001 9910674050303321 005 20210501 035 $a(CKB)5400000000042628 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/68880 035 $a(oapen)doab68880 035 $a(EXLCZ)995400000000042628 100 $a20202105d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aLassa Fever$eViral Replication, Disease Pathogenesis, and Host Immune Modulations 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 online resource (132 p.) 311 08$a3-03936-609-2 311 08$a3-03936-610-6 330 $aLassa virus causes Lassa fever disease in several countries in West Africa, where it is estimated to infect up to half million people causing roughly five thousand deaths each year. This deadly virus has also been introduced in multiple occasions into the western world, including the United States, United Kingdom, Netherlands, Sweden, and Germany. Lassa virus infection, which is often misdiagnosed, can lead to a wide range of disease symptoms ranging from mild flu-like symptoms to bleeding disorders, multi-organ failure, and death. Despite some major discoveries made in recent years of research on Lassa fever, there are still many unresolved key issues that hamper the development of effective vaccines and therapies. Some of these issues include a detailed understanding of the viral and participating host factors in completing the virus life cycle, in mediating disease pathogenesis or protection, and in activating or suppressing host immune responses against virus infection. This book is devoted to understanding some of these important issues. Expert and timely contributions in the form of editorial and original research and review articles on Lassa fever viral replication, disease pathogenesis and protection, host immune modulations, and other related hot topics are presented in this publication. 517 $aLassa Fever 606 $aBiology, life sciences$2bicssc 606 $aResearch & information: general$2bicssc 610 $aadaptive immunity 610 $aanimal models 610 $aarenavirus 610 $aarenaviruses 610 $aB cell anergy 610 $abroadly-neutralizing antibodies 610 $abudding 610 $acell-mediated immunity 610 $aconformational antigens 610 $aconserved antigens 610 $aCOVID-19 610 $across-restriction 610 $adominant and subdominant epitopes 610 $aentry 610 $aFc-gamma receptors 610 $afocused immunity 610 $afusion protein 610 $ainnate immunity 610 $ainterfering particles 610 $aLassa fever 610 $aLassa vaccine 610 $aLassa virus 610 $aLassa virus disease (LVD) 610 $aLassa virus vaccine 610 $aLASV 610 $alate domain 610 $amammarenavirus 610 $amass spectrometry 610 $amatrix protein 610 $amimicry 610 $aML29 vaccine 610 $aMopeia virus 610 $apathogenesis 610 $aphosphorylation 610 $aPPXY 610 $arelease 610 $areplication 610 $areplication-deficient MVA vector 610 $asingle-dose efficacy 610 $aSTAT-1-/- mice 610 $avaccine 610 $avaccine breadth 610 $aviral entry 610 $aviral fusion 610 $aviral glycoprotein 610 $aviral hemorrhagic fevers 610 $avirulence 610 $avirus-host interactions 610 $aVLP formation 610 $aZ protein 615 7$aBiology, life sciences 615 7$aResearch & information: general 700 $aLy$b Hinh$4edt$01339022 702 $aLy$b Hinh$4oth 906 $aBOOK 912 $a9910674050303321 996 $aLassa Fever$93059555 997 $aUNINA